


Searching News Database: prodrug
HSMN NewsFeed - 3 Nov 2021
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 12 Sep 2019
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 12 Nov 2018
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
HSMN NewsFeed - 15 Oct 2018
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
HSMN NewsFeed - 15 Feb 2017
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
HSMN NewsFeed - 15 Dec 2016
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
HSMN NewsFeed - 5 Oct 2016
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
HSMN NewsFeed - 7 Sep 2016
FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic
FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic
HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 4 Aug 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
HSMN NewsFeed - 24 Aug 2015
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
HSMN NewsFeed - 13 Jan 2015
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
HSMN NewsFeed - 5 Dec 2014
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
HSMN NewsFeed - 1 Dec 2014
Ascendis Pharma A/S Completes $60 million Oversubscribed Series D Financing
Ascendis Pharma A/S Completes $60 million Oversubscribed Series D Financing
HSMN NewsFeed - 3 Sep 2014
Celator(R) Pharmaceuticals Announces Appointment of Michael Dougherty as Chairman of the Board
Celator(R) Pharmaceuticals Announces Appointment of Michael Dougherty as Chairman of the Board
HSMN NewsFeed - 6 Jan 2014
Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 19 Dec 2013
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
HSMN NewsFeed - 24 Jul 2013
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
HSMN NewsFeed - 18 Dec 2012
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
HSMN NewsFeed - 5 Jun 2012
Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company Agenix
Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company Agenix
HSMN NewsFeed - 31 Oct 2011
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 7 Jun 2011
Cyterix Pharmaceuticals Raises $9.2 Million in a Series A Venture Financing
Cyterix Pharmaceuticals Raises $9.2 Million in a Series A Venture Financing
HSMN NewsFeed - 19 Nov 2010
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
HSMN NewsFeed - 5 Apr 2010
Qutenza(R) (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available
Qutenza(R) (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available
HSMN NewsFeed - 26 Jan 2010
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
HSMN NewsFeed - 17 Jul 2009
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
HSMN NewsFeed - 19 Mar 2009
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
HSMN NewsFeed - 19 Feb 2009
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
HSMN NewsFeed - 20 Jan 2009
Metabasis Therapeutics Announces Corporate Restructuring and Workforce Reduction
Metabasis Therapeutics Announces Corporate Restructuring and Workforce Reduction
HSMN NewsFeed - 14 Dec 2008
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
HSMN NewsFeed - 22 Oct 2008
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
HSMN NewsFeed - 3 Sep 2008
Access Pharmaceuticals Retains Piper Jaffray to Augment Strategic Partnering Efforts
Access Pharmaceuticals Retains Piper Jaffray to Augment Strategic Partnering Efforts
HSMN NewsFeed - 12 Aug 2008
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
HSMN NewsFeed - 9 Apr 2008
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
HSMN NewsFeed - 19 Mar 2008
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
HSMN NewsFeed - 27 Nov 2007
ImmunoGen, Inc. Hires John Tagliamonte as Vice President, Business Development
ImmunoGen, Inc. Hires John Tagliamonte as Vice President, Business Development
HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem announces important initiatives to provide medical and health benefits to patients
HSMN NewsFeed - 24 Oct 2007
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
HSMN NewsFeed - 22 Oct 2007
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
HSMN NewsFeed - 3 Oct 2007
ImmunoGen, Inc. Hires Craig Barrows as Vice President, General Counsel and Secretary
ImmunoGen, Inc. Hires Craig Barrows as Vice President, General Counsel and Secretary
HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
HSMN NewsFeed - 27 Apr 2007
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial Sites
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial Sites
HSMN NewsFeed - 19 Apr 2007
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
HSMN NewsFeed - 19 Apr 2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
HSMN NewsFeed - 10 Apr 2007
FermaVir Pharmaceuticals, Inc. Signs Definitive Agreement to Be Acquired by Inhibitex, Inc.
FermaVir Pharmaceuticals, Inc. Signs Definitive Agreement to Be Acquired by Inhibitex, Inc.
HSMN NewsFeed - 22 Feb 2007
VistaGen Therapeutics Names Dr. Matthew W. Kalnik as Executive Vice President
VistaGen Therapeutics Names Dr. Matthew W. Kalnik as Executive Vice President
HSMN NewsFeed - 21 Feb 2007
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
HSMN NewsFeed - 8 Feb 2007
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
HSMN NewsFeed - 17 Jan 2007
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
HSMN NewsFeed - 3 Jan 2007
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
HSMN NewsFeed - 26 Dec 2006
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
HSMN NewsFeed - 17 May 2006
John Gutheil, M.D., Joins Proacta as Chief Medical Officer and Senior Vice President of Clinical Affairs
John Gutheil, M.D., Joins Proacta as Chief Medical Officer and Senior Vice President of Clinical Affairs
HSMN NewsFeed - 11 May 2006
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
HSMN NewsFeed - 4 May 2006
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
Additional items found! 130
Members Archive contains
130 additional stories matching:
prodrug
(Password required)
prodrug
(Password required)
